Journal profile · Pathology
Expert Review of Molecular Diagnostics
ISSN 1473-7159 · eISSN 1744-8352 · Taylor and Francis Ltd. · ENGLAND · Bimonthly · Founded 2001
Expert Review of Molecular Diagnostics: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.42; JCR Q1 (journal website); hybrid open access; APC charged, amount not published; median 108 days to acceptance (98 articles, last 24 months); community-reported acceptance: moderate; 91 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Review of Molecular Diagnostics is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Genomics and Diagnostics, Molecular Biology Techniques and Applications and Biosensors and Analytical Detection, together about 26.5% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Expert Review of Molecular Diagnostics [ISSN 1473-7159]; [e-ISSN 1744-8352] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers in molecular diagnostics. The journal covers the detection and monitoring of the molecular causes of disease that are being translated into ground-breaking diagnostic and prognostic technologies to be used in the clinical diagnostic setting. Expert Review of Molecular Diagnostics provides a forum for reporting the critical advances being made in this ever-expanding field, as well as the major challenges ahead in their clinical implementation. The journal delivers this information in concise, at-a-glance article formats: invaluable to a time-constrained community. Articles focus on the following key areas: Contemporary genetic and genomic technologies including deep sequencing and genome-wide association studies. Molecular tools for infectious disease testing and detection of multiple resistant bacteria. Latest discoveries in oncology diagnostics. Progress in non-invasive prenatal testing, including molecular markers and ethical considerations. 'Omic’ diagnostic technologies including: pharmacogenomic, epigenomic, proteomic and metabolomic technologies. Disease predisposition and inherited genetic diseases testing. Diagnostic tests for point-of-care settings and for resource-limited settings as well as progress in developing handheld devices for molecular diagnostic tests. Progress in developing handheld devices for molecular diagnostic tests. Biomarker development and usage to target patient groups for personalized medicine. Tools for molecular prognosis. Novel technologies and developments in molecular diagnostic techniques. Regulatory, ethical and payor perspectives in molecular diagnostics. Each issue of Expert Review of Molecular Diagnostics contains: Reviews on current and emerging topics relating to molecular diagnostics. Editorials discussing contentious issues in the field. Diagnostic profiles featuring independent, expert evaluations of diagnostic tests. Original Research - manuscripts detailing clinical studies with a presentation of previously unpublished data. Please note that the journal does not publish case reports or case series. Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a disc
From the journal's Aims & Scope
Research area (LetPub): Pathology
Editor-in-chief Attila T LorinczPublisher website
Editorial board by country: none in mainland China; most named United States 14, United Kingdom 4, Hong Kong, China 3, Australia 3, Germany 2 (35 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology13.5%
- Molecular Biology Techniques and ApplicationsBiochemistry, Genetics and Molecular Biology7.2%
- Biosensors and Analytical DetectionEngineering5.9%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology5%
- Advanced biosensing and bioanalysis techniquesBiochemistry, Genetics and Molecular Biology4.7%
- Advanced Biosensing Techniques and ApplicationsBiochemistry, Genetics and Molecular Biology4.1%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4%
- Genomics and Rare DiseasesBiochemistry, Genetics and Molecular Biology4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pathology | Zone 3 |
Top journal: noReview journal: yes
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
- CiteScore Q1 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCurrent ContentsPublisher website
Other: Index Medicus, Biobase, Biotechnology Citation Index™, Index to Scientific Reviews®, Journal Citation Reports/Science Edition®
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.42LetPub ·
- Impact factor (publisher) 2025
- 4.3Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.1Publisher website ·
- CiteScore 2026-06
- 6.8LetPub ·
- CiteScore (publisher) 2025
- 6.8Publisher website ·
- SJR 2026-06
- 1.03LetPub ·
- SJR (publisher) 2025
- 1.03Publisher website ·
- SNIP 2026-06
- 1.02LetPub ·
- SNIP (publisher) 2025
- 1.02Publisher website ·
- h-index
- 68LetPub ·
- h-index
- 105OpenAlex ·
- i10-index
- 1,576OpenAlex ·
- 2-year mean citedness
- 4.64OpenAlex ·
- Self-citation rate
- 2.3%LetPub ·
- Share of gold OA articles
- 6.51%LetPub ·
Volume
- Articles per year
- 70LetPub ·
- Downloads per year (publisher)
- 291,000Publisher website ·
- Downloads per year (publisher) 2025
- 291,000Publisher website ·
Articles by year OpenAlex count · 2,568 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 70 | 18 | 24 |
| 2025 | 91 | 32 | 315 |
| 2024 | 86 | 24 | 806 |
| 2023 | 121 | 41 | 1,375 |
| 2022 | 78 | 25 | 1,173 |
| 2021 | 138 | 59 | 2,819 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
108 daysMedian, submission to acceptance · P25–P75 74 days – 146 days
- Acceptance to online
- median 7 days (98 articles)
- Submission to online
- median 118 days
- Sample
- 98 articles with submission and acceptance dates (184 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
- Acceptance rate (publisher)
- 13%Publisher website ·
- Acceptance rate (publisher) 2025
- 13%Publisher website ·
- Submission to first decision
- 8 daysPublisher website ·
- Submission to first decision 2025
- 8 daysPublisher website ·
- First decision after review
- 49 daysPublisher website ·
- First decision after review 2025
- 49 daysPublisher website ·
- Acceptance to publication
- 9 daysPublisher website ·
- Acceptance to publication 2025
- 9 daysPublisher website ·
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted4
- diagnostic profilesDiagnostic profiles featuring independent, expert evaluations of diagnostic tests.Length not stated
- editorialsEditorials discussing contentious issues in the field.Length not stated
- original researchOriginal Research - manuscripts detailing clinical studies with a presentation of previously unpublished data.Length not stated
- review articlesReviews on current and emerging topics relating to molecular diagnostics.Length not stated
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
Expert Review of Molecular Diagnostics is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the disc…
Source ↗Publisher website ·- Peer review
No case reports or case series Model summary
Please note that the journal does not publish case reports or case series.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2001
- ISSN
- 1473-7159
- Electronic ISSN
- 1744-8352
- Latest issue on the website
- Volume 26, Issue 9 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Expert Review of Molecular Diagnostics
What CAS zone is Expert Review of Molecular Diagnostics in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Review of Molecular Diagnostics is in Zone 3 of Medicine, and in Zone 3 of the minor category Pathology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Review of Molecular Diagnostics?
The latest impact factor listed by LetPub is 4.42; CiteScore 6.8, h-index 105.
How long does peer review take at Expert Review of Molecular Diagnostics?
Based on the dates recorded on 98 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 108 days (interquartile range 74–146 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”; the journal's website gives an acceptance rate of 13% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Expert Review of Molecular Diagnostics in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Expert Review of Molecular Diagnostics based?
Of the 35 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (14), United Kingdom (4) and Hong Kong, China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Expert Review of Molecular Diagnostics?
According to LetPub and DOAJ records, Expert Review of Molecular Diagnostics is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase, CAS and Current Contents; that list has not been checked against each database.
Is Expert Review of Molecular Diagnostics open access, and what is the APC?
Expert Review of Molecular Diagnostics is a hybrid journal. For open-access publication: APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .